(PubMed) Hurst R, Armah CN, Dainty JR, et al
While early open-label and phase 2 trials suggested potential benefits of arbaclofen in children with ASD, subsequent phase 3 randomized controlled trials failed to demonstrate significant efficacy over placebo on primary outcomes, despite favorable safety and tolerability profiles
This suggests that people with metabolic dysfunction may experience more rapid initial benefits, such as appetite suppression, as the medication begins to correct these imbalances, says Dr
It has a well-support safety profile: a comprehensive 2025 review found minimal toxicity with no evidence of carcinogenicity
A single-bout exercise experiment was performed following 2 weeks of glutathione (1 g/d) or placebo supplementation in capsule form
Its easy to assume they work like medicationsespecially when influencers or ads use medical-sounding language